Get In Touch

Cardiovascular diseases is one of the major causes of deaths across the globe and the rate of mortality caused by these diseases is expected to reach over 23 million by 2030, according to the World Health Organization. Cardiovascular conditions are largely lifestyle diseases and about 16% of deaths caused by cardiovascular diseases in 2012 were attributable to high blood pressure. Various classes of drugs used for treating cardiac disorders include calcium channel blockers, anti-adrenergic agents, anti-arrhythmic agents, diuretic agents, and angiotensin-converting enzyme (ACE) inhibitors. Anti-adrenergic agents have been recognized as an imperative therapeutic intervention in the treatment of patients with cardiac ailments. Anti-adrenergic agents act by inhibiting the stimulation of the central nervous system and ultimately, by reducing the sympathetic stimulation to the blood vessels and the heart. They primarily block the adrenergic receptors and inhibit their activity. Anti-adrenergic agents reduce the heart rate and relax the blood vessels, which ultimately reduces the blood pressure. This is helpful in treating conditions such as hypertension, angina, and arrhythmia.

Therapeutic innovations, increased disease awareness, and government intervention in curbing the number of deaths caused by cardiovascular diseases have helped in reducing the mortality rate. Statistics published by the American Health Association suggests that the mortality rate per 100,000 reduced from 342.9 in 2000 to 236.6 in 2010 in the U.S. Statins is a major drug class that includes blockbuster drugs such as Lipitor (atorvastatin calcium) and Crestor (rosuvastatin). However, the percentage of prescribing of these drugs in hospital settings is negligible compared to other cardiovascular drugs such as Novarsc (amlodipine), Diovan (valsartan), and VESIcare (solifenacin succinate). The global antiadrenergic agents market for cardiology was valued at US$ 452.6 Mn in 2013 and is expected to expand at a moderate pace during the forecast period.

The global antiadrenergic agents market can be segmented based on type, distribution channel, and region. Based on type, the market can be divided into α blockers and β blockers. The α blockers segment can be further categorized into equilibrium type and non-equilibrium type. The equilibrium type of α blockers further comprise selective and non-selective antiadrenergic drugs. Selective drugs consist of α1 selective drugs and α2 selective drugs. Similarly, β blockers have been divided into non-selective β blockers and selective β blockers. Non-selective β blockers exhibit membrane-stabilizing activity without intrinsic sympathomimetic activity. Some examples of non-selective β Blockers are timolol, propranolol, and sotalol. Examples of selective β blockers include atenolol, metoprolol, acebutolol, esmolol, and butoxamine. Based on distribution channel, the global antiadrenergic agents market can be segmented into hospital pharmacies, clinics, hospitals, retail pharmacies, and online pharmacies.

Based on geography, the global antiadrenergic agents market can be segmented into North America, Europe, Asia Pacific, and Rest of World. North America accounts for a major market share owing to extensive research and development activities, favorable reimbursement policies, and advanced health care infrastructure in the region. Implementation of the Affordable Care Act has imposed significant limitations on hospitals as well as pharmaceutical companies with respect to costing of new drugs. Europe follows North America in the market for antiadrenergic agents, due to comprehensive intellectual property protection and presence of companies and organizations involved in research in the region. However, lack of proper reimbursement and regulatory framework pertaining to new drug development is a key restraint to the market in Europe. Increasing prevalence of cardiovascular diseases in other regions of the world is likely to boost the antiadrenergic agents market in these regions during the forecast period.

Key players operating in the global antiadrenergic agents market are Boehringer Ingelheim GmbH, Pliva, AstraZeneca plc, Pfizer, Inc. and GlaxoSmithKline plc.

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

REQUEST CUSTOMIZATION

Anti Adrenergic Agents Market